Result

Chemotherapy treatment:

Among the 200 patients, chemotherapy was almost equally distributed between the two treatment groups. 98 patients (49%) received Drug A, while 102 patients (51%) received Drug B, indicating a relatively balanced allocation between the treatment groups.

Age:

The median age of the patients was 47 years (IQR: 38–57 years). Age information was unavailable for 11 patients, suggesting that the age distribution was generally centered around middle adulthood.

Marker level:

The median marker level was 0.64 ng/mL (IQR: 0.22–1.41 ng/mL). Marker measurements were unavailable for 10 patients. The relatively wide interquartile range indicates considerable variability in marker levels across patients.

T stage:

The distribution of tumor stage was relatively balanced. 53 patients (27%) were classified as T1, 54 (27%) as T2, 43 (22%) as T3, and 50 (25%) as T4. Thus, patients were represented across all tumor stages, with T1 and T2 being slightly more common than T3 and T4.

Tumor grade:

Regarding tumor grade, 68 patients (34%) had Grade I, 68 (34%) had Grade II, and 64 (32%) had Grade III disease. The nearly equal distribution across the three grades suggests that the study population included a broad range of tumor differentiation/severity.

Tumor response:

A documented tumor response was observed in 61 patients (32%), while the response status was unknown for 7 patients. This indicates that approximately one-third of the study population had a recorded tumor response, although the specific definition and categories of response (e.g., complete response, partial response, stable disease, progression) should be clarified in the table or methods.

Mortality:

During follow-up, 112 of the 200 patients (56%) died, indicating a substantial mortality burden in this cohort. The remaining patients were either alive at the end of follow-up or censored.

Time to death/censoring:

The median follow-up time, represented by months to death or censoring, was 22.4 months (IQR: 15.9–24.0 months). This indicates that half of the patients experienced death or were censored within approximately 22 months, while the middle 50% of observations occurred between about 16 and 24 months.

Overall interpretation:

Overall, the cohort consisted of 200 patients with a balanced distribution of chemotherapy treatment groups and relatively even distributions of tumor stage and grade. The median patient age was 47 years, and more than half of the patients died during follow-up. The median time to death or censoring was approximately 22 months, providing a reasonable basis for subsequent survival analysis, such as Kaplan–Meier estimation and Cox proportional hazards regression.

head(trial)

Characteristic	N = 200¹
Chemotherapy Treatment
Drug A	98 (49%)
Drug B	102 (51%)
Age	47 (38, 57)
Unknown	11
Marker Level (ng/mL)	0.64 (0.22, 1.41)
Unknown	10
T Stage
T1	53 (27%)
T2	54 (27%)
T3	43 (22%)
T4	50 (25%)
Grade
I	68 (34%)
II	68 (34%)
III	64 (32%)
Tumor Response	61 (32%)
Unknown	7
Patient Died	112 (56%)
Months to Death/Censor	22.4 (15.9, 24.0)
¹ n (%); Median (Q1, Q3)

plot(trial$age,trial$ttdeath)

trial %>% 
  tbl_summary(
    by=trt
  )

Characteristic	Drug A N = 98¹	Drug B N = 102¹
Age	46 (37, 60)	48 (39, 56)
Unknown	7	4
Marker Level (ng/mL)	0.84 (0.23, 1.60)	0.52 (0.18, 1.21)
Unknown	6	4
T Stage
T1	28 (29%)	25 (25%)
T2	25 (26%)	29 (28%)
T3	22 (22%)	21 (21%)
T4	23 (23%)	27 (26%)
Grade
I	35 (36%)	33 (32%)
II	32 (33%)	36 (35%)
III	31 (32%)	33 (32%)
Tumor Response	28 (29%)	33 (34%)
Unknown	3	4
Patient Died	52 (53%)	60 (59%)
Months to Death/Censor	23.5 (17.4, 24.0)	21.2 (14.5, 24.0)
¹ Median (Q1, Q3); n (%)